The National Health Surveillance Agency (Anvisa) held a workshop focused on the reliance model, a regulatory strategy that facilitates and accelerates the registration process for medicines, biological products, and bioactive complexes of natural origin (CBPF).
The event represents an important step in modernizing Brazilian regulatory procedures. The reliance model allows the agency to rely on evaluations and decisions from other internationally recognized health authorities, reducing the time needed for dossier analysis and approval of new drugs in the country.
This mechanism is particularly relevant for medicines and biological products that have already undergone rigorous evaluation in other jurisdictions with equivalent regulatory standards. By adopting reliance, Anvisa not only optimizes its resources but also offers developers a more efficient pathway to bring innovations to the Brazilian market.
For biological products, this approach is especially significant, as it recognizes the complexity and time invested in clinical and non-clinical studies. As for bioactive complexes of natural origin, reliance represents an opportunity to value Brazilian biodiversity by facilitating the development of innovative products based on natural resources.
The workshop reflects Anvisa's commitment to harmonizing its processes with international best practices while maintaining scientific rigor and safety. The initiative also contributes to the competitiveness of the national pharmaceutical industry on the global stage, allowing Brazilian companies to have faster access to the same mechanisms used in developed markets.
The promotion of this event demonstrates that the agency is committed to creating a more agile regulatory environment without compromising the quality and safety standards expected by regulatory bodies.
